PEGylation strategies for active targeting of PLA/PLGA nanoparticles

Journal of Biomedical Materials Research - Part A

Volumn 91, Issue 1, 2009, Pages 263-276

  Betancourt, Tania ^a   Byrne, James D ^a   Sunaryo, Nicole ^a   Crowder, Spencer W ^a   Kadapakkam, Meena ^a   Patel, Shefali ^a   Casciato, Shelly ^b   Brannon Peppas, Lisa ^a,c  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c Appian Labs LLC   (United States)

Author keywords

Poloxamer; Poly(ethylene glycol); Poly(lactic acid); Poly(lactic co glycolic acid); Targeted delivery

Indexed keywords

ACTIVE TARGETING; BIODEGRADABLE NANOPARTICLE; CARBODIIMIDE CHEMISTRY; FUNCTIONAL SITES; GLYCOLIDE; HYDROXYL GROUPS; PEGYLATION; POLOXAMER; POLY(LACTIC ACID); POLY(LACTIC-CO-GLYCOLIC ACID); POLYLACTIC ACIDS; POLYMERIZATION OF LACTIDE; SURFACE CONJUGATION; SURFACE LOCALIZATION; TARGETED DELIVERY;

BLENDING; BLOCK COPOLYMERS; BODY FLUIDS; COPOLYMERIZATION; ETHYLENE; ETHYLENE GLYCOL; LACTIC ACID; NANOPARTICLES; OLIGOMERS; ORGANIC ACIDS; POLYETHYLENE OXIDES; SURFACE PROPERTIES;

POLYETHYLENE GLYCOLS;

CYANAMIDE; IMMUNOGLOBULIN; MACROGOL; NANOPARTICLE; POLOXAMER; POLYGLACTIN; POLYLACTIC ACID;

ARTICLE; BIODEGRADABILITY; CONTROLLED STUDY; MOUSE; NANOFABRICATION; NONHUMAN; POLYMERIZATION; SURFACE PROPERTY; SYNTHESIS;

ANIMALS; DRUG DELIVERY SYSTEMS; IMMUNOCONJUGATES; LACTIC ACID; MICE; NANOPARTICLES; POLOXAMER; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; POLYMERS; SURFACE PROPERTIES;

EID: 70349087411     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.32247     Document Type: Article

References (50)

1. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004;56:1649-1659. (Pubitemid 39177694)
2. Fawaz F, Bonini F, Guyot M, Langueny AM, Fessi H, Devissaguet JP. Influence of poly(DL-lactide) on the biliary clearance and enterohepatic circulation of indomethacin in the rabbit. Pharm Res 1993;10:750-756. (Pubitemid 23152324)
3. Avgoustakis K. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: Preparation, properties and possible applications in drug delivery. Curr Drug Deliv 2004;1:321-333.
4. Mehvar R. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J Pharm Pharm Sci 2000;3:125-136.
5. Hu RG, Zhai QW, He WJ, Mei L, Liu WY. Bioactivities of ricin retained and its immunoreactivity to anti-ricin polyclonal antibodies alleviated through pegylation. Int J Biochem Cell Biol 2002;34:396-402. (Pubitemid 34164282)
6. Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoaprticles for biological and pharmaceutical applications. Adv Drug Deliv Rev 2003;55:403-419. (Pubitemid 36293792)
7. Stolnik S, Dunn SE, Garnett MC, Davies MC, Coombes AG, Taylor DC, Irving MP, Purkiss SC, Tadros TF, Davis SS, Illum L. Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)- poly(ethylene glycol) copolymers. Pharm Res 1994;11:1800-1808.
8. Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Muller RH. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): Influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 2000;18(3/4):301-313.
9. Torchilin VP, Narula J, Halpern E, Khaw BA. Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: Factors influencing targeted accumulation in the infarcted myocardium. Biochimica Biophysica Acta 1996;1279:75-83. (Pubitemid 26067420)
10. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994;263:1600-1603.
11. Li Y, Pei Y, Zhang X, Gu Z, Zhou Z, Yuan W, Zhou J, Zhu J, Gao X. PEGylated PLGA nanoparticles as protein carriers: Synthesis, preparation and biodistribution in rats. J Control Release 2001;71:203-211. (Pubitemid 32234381)
12. Torchilin VP. Which polymer can make nanoparticulate drug carriers long-circulating? Adv Drug Deliv Rev 1995;16(2/3):141-155.
13. Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Livaniou E, Evangelatos G, Ithakissios DS. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. Int J Pharm 2003;259(1/2):115-127. (Pubitemid 36638559)
14. Beletsi A, Leontiadis L, Klepetsanis P, Ithakissios DS, Avgoustakis K. Effect of preparative variables on the properties of poly(dl-lactide-co- glycolide)-methoxypoly(ethyleneglycol) copolymers related to their application in controlled drug delivery. Int J Pharm 1999;182:187-197. (Pubitemid 29248847)
15. Zambaux MF, Bonneaux F, Gref R, Dellacherie E, Vigneron C. MPEO-PLA nanoparticles: Effect of MPEO content on some of their surface properties. J Biomed Mater Res 1999;44:109-115. (Pubitemid 28544091)
16. Salem AK, Cannizzaro SM, Davies MC, Tendler SJ, Roberts CJ, Williams PM, Shakesheff KM. Synthesis and characterisation of a degradable poly(lactic acid)-poly(ethylene glycol) copolymer with biotinylated end groups. Biomacromolecules 2001;2:575-580.
17. Cannizzaro SM, Padera RF, Langer R, Rogers RA, Black FE, Davies MC, Tendler SJ, Shakesheff KM. A novel biotinylated degradable polymer for cell-interactive applications. Biotechnol Bioeng 1998;58:529-535. (Pubitemid 28178255)
18. Gref R, Couvreur P, Barratt G, Mysiakine E. Surface-engineered nanoparticles for multiple ligand coupling. Biomaterials 2003;24:4529-4537. (Pubitemid 36960147)
19. Gao X, Tao W, Lu W, Zhang Q, Zhang Y, Jiang X, Fu S. Lectin- conjugated PEG-PLA nanoparticles: Preparation and brain delivery after intranasal administration. Biomaterials 2006;27:3482-3490.
20. Skoog B. Determination of polyethylene glycols 4000 and 6000 in plasma protein preparations. Vox Sang 1979;37:345-349. (Pubitemid 10131371)
21. Hermanson GT. Bioconjugate Techniques. San Diego, CA: Academic Press; 1996. 785 p.
22. Staros JV. N-hydroxysuccinimide active esters: Bis(N- hydroxysulfosuccinimide) esters of two dicarboxylic acids are hydrophilic, membrane impermeant, protein cross-linkers. Biochemistry 1982;21:3950-3955.
23. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006;103:6315-6320.
24. Kasturi SP, Sachaphibulkij K, Roy K. Covalent conjugation of polyethyleneimine on biodegradable microparticles for delivery of plasmid DNA vaccines. Biomaterials 2005;26:6375-6385. (Pubitemid 40828393)
25. Kricheldrof HR, Meier-Haack J. Polylactones. XXII: ABA triblock copolymers of L-lactide and poly(ethylene glycol). J Makromol Chem 1993;194:715-725.
26. Vila A, Gill H, McCallion O, Alonso MJ. Transport of PLA-PEG particles across the nasal mucosa: Effect of particle size and PEG coating density. J Control Release 2004;98:231-244. (Pubitemid 38950733)
27. Vila A, Sanchez A, Evora C, Soriano I, McCallion O, Alonso MJ. PLA-PEG particles as nasal protein carriers: the influence of the particle size. Int J Pharm 2005;292(1/2):43-52. (Pubitemid 40255787)
28. Perez C, Sanchez A, Putnam D, Ting D, Langer R, Alonso MJ. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J Control Release 2001;75(1/2):211-224. (Pubitemid 32635211)
29. Du YJ, Lemstra PJ, Nijenhuis AJ, van Aert HAM, Bastiaansen C. ABA type copolymers of lactide with poly(ethylene glycol). Kinetic, mechanistic, and model studies. Macromolecules 1995;28:2124-2132.
30. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. Nanoparticle-aptamer bioconjugates: A new approach for targeting prostate cancer cells. Cancer Res 2004;64:7668-7672. (Pubitemid 39446893)
31. Hrkach JS, Peracchia MT, Domb A, Lotan N, Langer R. Nanotechnology for biomaterials engineering: Structural characterization of amphiphilic polymeric nanoparticles by 1H NMR spectroscopy. Biomaterials 1997;18:27-30. (Pubitemid 27029712)
32. Heald CR, Stolnik S, Kujawinski KS, De Matteis C, Garnett MC, Illum L, Davis SS, Purkiss SC, Barlow RJ, Gellert PR. Poly(lactic acid)-poly(ethylene oxide) (PLA-PEG) nanoparticles: NMR studies of the central solid like PLA core and the liquid PEG corona. Langmuir 2002;18:3669-3675. (Pubitemid 35383731)
33. Garcia-Fuentes M, Torres D, Martin-Pastor M, Alonso MJ. Application of NMR spectroscopy to the characterization of PEG-stabilized lipid nanoparticles. Langmuir 2004;20:8839-8845.
34. Fessi H, Devissaguet JP, Puisieux F, Thies C. Procédé de préparation des systèmes colloÿdaux dispersibles dune substance sous forme de nanoparticules. French Patent 2,608,988;1986.
35. Barichello JM, Morishita M, Takayama K, Nagai T. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm 1999;25:471-476. (Pubitemid 29159426)
36. Betancourt T, Brown B, Brannon-Peppas L. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: Preparation, characterization and in vitro evaluation. Nanomedicine 2007;2:219-232. (Pubitemid 46845768)
37. Lowery AR, Gobin AM, Day ES, Halas NJ, West JL. Immunonanoshells for targeted photothermal ablation of tumor cells. Int J Nanomed 2006;1:149-154.
38. Josephy PD, Thomas E, Mason RP. The horseradish peroxidase-catalyzed oxidation of 3,5,3′,5′-tetramethylbenzidine. J Biol Chem 1982;257:3669-3675.
39. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
40. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: Formulation, process and storage considerations. Adv Drug Deliv Rev 2006;58:1688-1713. (Pubitemid 44827432)
41. de Jaeghere F, Allemann E, Feijen J, Kissel T, Doelker E, Gurny R. Freeze-drying and lyopreservation of diblock and triblock poly(lactic acid)-poly(ethylene oxide) (PLA-PEO) copolymer nanoparticles. Pharm Dev Technol 2000;5:473-483.
42. Quellec P, Gref R, Perrin L, Dellacherie E, Sommer F, Verbavatz JM, Alonso MJ. Protein encapsulation within polyethylene glycol-coated nanospheres. I. Physicochemical characterization. J Biomed Mater Res 1998;42:45-54.
43. Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 1995;17:31-48.
44. Moghimi SM, Hunter AC. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends Biotechnol 2000;18:412-420.
45. Csaba N, Caamano P, Sanchez A, Dominguez F, Alonso MJ. PLGA:poloxamer and PLGA:poloxamine blend nanoparticles: New carriers for gene delivery. Biomacromolecules 2005;6:271-278. (Pubitemid 40277024)
46. Csaba N, Sanchez A, Alonso MJ. PLGA:poloxamer and PLGA:poloxamine blend nanostructures as carriers for nasal gene delivery. J Control Release 2006;113:164-172. (Pubitemid 43928142)
47. Santander-Ortega MJ, Jodar-Reyes AB, Csaba N, Bastos- Gonzalez D, Ortega-Vinuesa JL. Colloidal stability of pluronic F68-coated PLGA nanoparticles: A variety of stabilisation mechanisms. J Colloid Interface Sci 2006;302:522-529. (Pubitemid 44348977)
48. Neal JC, Stolnik S, Garnett MC, Davis SS, Illum L. Modification of the copolymers poloxamer 407 and poloxamine 908 can affect the physical and biological properties of surface modified nanospheres. Pharm Res 1998;15:318-324. (Pubitemid 28144247)
49. Gilding DK, Reed AM. Biodegradable polymers for use in surgery-polyglycolic/poly(lactic acid) homo- and copolymers: Part 1. Polymer 1979;20:1459-1464. (Pubitemid 10435422)
50. Middleton JC, Tipton AJ. Synthetic biodegradable polymers as orthopedic devices. Biomaterials 2000;21:2335-2346